...$176 million over the first five years. GSK; Lonza Group Ltd. (SIX:LONN, Basel, Switzerland); and Kalon Biotherapeutics LLC...

...Emirates government; U.K. government; U.S. government; World Health Organization >785 Emergent BioSolutions Inc. (NYSE:EBS); GlaxoSmithKline; Kalon Biotherapeutics LLC...

...therapeutics 10.6 Mirna Therapeutics Inc. Cancer treatment including drug discovery, development and clinical trials 10.3 Kalon Biotherapeutics LLC...

...will support operation and maintenance costs in subsequent years. Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Kalon Biotherapeutics LLC...

...million over the first five years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Lonza Group Ltd. (SIX:LONN); and Kalon Biotherapeutics LLC...

...receiving money in the latest grant round: RNA diagnostics company Asuragen Inc. , biomanufacturing company Kalon Biotherapeutics LLC...
...Prevention & Research Institute of Texas , Austin, Texas Cell Medica Ltd. , London, U.K. Kalon Biotherapeutics LLC...
...by next-generation DNA sequencing 6.8 Cell Medica Ltd. Clinical development of T cell therapies 15.6 Kalon Biotherapeutics LLC...

...million grant, will move its headquarters to Texas. Other biotech grants included $7.9 million to Kalon Biotherapeutics LLC...